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Background: There have been no major advances in tuberculosis (TB) drug development since the first East
African/British Medical Research Council short course chemotherapy trial 35 years ago. Since then, the landscape for
conducting TB clinical trials has profoundly changed with the emergence of HIV infection, the spread of resistant TB
bacilli strains, recent advances in mycobacteriological capacity, and drug discovery. As a consequence questions
have arisen on the most appropriate approach to design and conduct current TB trials. To highlight key issues
discussed: Is a superiority, equivalence, or non-inferiority design most appropriate? What should be the primary
efficacy outcome? How to consider re-infections in the definition of the outcome? What is the optimal length of
patient follow-up? Is blinding appropriate when treatment duration in test arm is shorter? What are the appropriate
assumptions for sample size calculation?
Methods: Various drugs are currently in the development pipeline. We are presenting in this paper the design of
the most recently completed phase III TB trial, the OFLOTUB project, which is the pivotal trial of a registration
portfolio for a gatifloxacin-containing TB regimen. It is a randomized, open-label, multicenter, controlled trial aiming
to evaluate the efficacy and safety of a gatifloxacin-containing 4-month regimen (trial registration: ClinicalTrial.gov
database: NCT00216385).
Results: In the light of the recent scientific and regulatory discussions, we discuss some of the design issues in TB
clinical trials and more specifically the reasons that guided our choices, in order to best answer the trial objectives,
while at the same time satisfying regulatory authority requirements.
Conclusion: When shortening TB treatment, we are advocating for a non-inferiority, non-blinded design, with a
composite unfavorable endpoint assessed 12 months post treatment completion, and added trial procedures
specifically aiming to: (1) minimize endpoint unavailability; and (2) distinguish between relapse and re-infection.
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Tuberculosis (TB) has long been neglected as a public
health problem and remains, with HIV/AIDS, one of the
most important cause of death from a single infectious
agent among adults in developing countries [1,2]. There
were an estimated 8.8 million new TB cases in 2010 [3].
Drug susceptible TB is currently treated with a 6-month
course regimen: 2 months intensive phase of daily iso-
niazid, rifampicin, pyrazinamide, and ethambutol fol-
lowed by 4 months continuous phase of daily isoniazid
and rifampicin [4]. While generally effective with proper
compliance, in practice patients may fail to adhere to
treatment at any time and default. The consequences
may be treatment failure for the individual patient but
also, for the general population, the risk of the emer-
gence and spread of resistance when the inadequate
treatment selected for drug-resistant bacteria. A shorter
duration of treatment is expected to provide improved
patient adherence and better treatment outcome.
Shortening the duration of treatment has been recog-
nized by both the World Health Organization (WHO)
Stop TB and the Global Alliance for TB Drug Develop-
ment (GATB) as a major target for the improvement of
TB control worldwide [3]. Furthermore, at the time of
developing this study new compounds for TB treatment
were still at the early stage of clinical development, and
investigation of the effect of existing drugs was a prior-
ity. The fluoroquinolones have proven to be useful in
the management of multidrug-resistant TB, and have
been proposed for shortening first-line treatment of
pan-susceptible TB [5-7]. Evidence for the potential
shortening of treatment using fluoroquinolones was first
provided in observational studies where ofloxacin
replaced ethambutol in India [8]. The third generationTable 1 Treatment regimens
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Ethambutol 275 mgfluoroquinolones, gatifloxacin and moxifloxacin, have
been shown to have better bactericidal activity than
ofloxacin in vitro and in vivo [6], and confirmed by a
serial sputum colony counts phase II study [9]. It was
therefore considered by authorities in the field (includ-
ing WHO Stop TB, GATB, and WHO/TDR) that proper
investigation of the third generation fluoroquinolones
was justified, and should be pursued. The choice of gati-
floxacin as the molecule under investigation in the
OFLOTUB trial was based on its bactericidal activity
profile and its generic status.
In this paper we present issues that arose in the design
of the trial, with emphasis on salient methodological
aspects that have been source of various discussions
within the team and with regulatory authorities.Methods
Overview of OFLOTUB
OFLOTUB is a pivotal phase III, randomized, open-label,
parallel group, multicenter trial included in the registra-
tion portfolio for a gatifloxacin-containing TB regimen.
The objective of the trial is to evaluate the efficacy and
safety of a gatifloxacin-containing 4-month regimen (test
regimen) in the treatment of pulmonary TB in com-
parison with the standard WHO-recommended 6-month
regimen (reference regimen) (Table 1). Subjects were ran-
domized in a ratio of 1:1 to receive either the test or
standard regimen. Randomization was stratified by coun-
try and conducted using sealed envelopes. Each patient is
followed for 24 months after the end of treatment. The
trial has been designed to comply with GCP/ICH guide-
lines (details on the implementation of these for our trial
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Patients were recruited in five sites in Africa: Benin
(Cotonou, National TB program); Guinea (Conakry, Na-
tional TB program); Kenya (Nairobi, KEMRI); Senegal
(Dakar, National TB program); and South Africa (Durban,
MRC). All trial products were provided by Lupin Pharma-
ceuticals, Mumbai, India. Thammasat University, Bangkok,
Thailand is responsible for the central data management of
the trial in collaboration with the local data-management
teams based in each of the recruitment sites.
Trial governance
The trial is co-sponsored by the Institut de recherche
pour le developpement (IRD) and the UNICEF/UNPD/
World Bank/WHO Special Program for Research and
Training in Tropical Disease (TDR) and the whole drug
development project is coordinated by the TDR secretar-
iat. Two committees were initially established: A Trial
Steering Committee (TSC) and a Product Development
Team (PDT). The TSC monitors the conduct of the
phase III trial and is composed of the Principal Investi-
gators (PI) from each of the recruitment sites and the
PIs from the other collaborating institutions: Assistance
Publique - Hôpitaux de Paris, Institut de Recherche et
Developpement (IRD), France; London School of Hy-
giene and Tropical Medicine (LSHTM); St Georges Hos-
pital Medical School (UK); and the Institute of Tropical
Medicine in Antwerp, Belgium. The PDT is composed
of four independent scientists and the two co-sponsor
representatives and has an over-view of the whole Gati-
floxacin for TB drug development portfolio.
A Data Monitoring Committee (DMC) composed of
three independent scientists monitored the safety
aspects of the Phase III trial. They convened every
6 months until all patients completed treatment and
30 days of follow-up.
The trial protocol was reviewed and approved by all
central and local Institutional Review Boards. The trial is
registered in the ClinicalTrial.gov database with the
registration number: NCT00216385.
Recruitment of patients
Male and female patients, aged 18 to 65 years, suffering
from recently diagnosed, microscopically proven, pul-
monary tuberculosis, and providing informed consent
for inclusion in the trial, were considered for enrolment.
The full list of inclusion and exclusion criteria is pre-
sented in Table 2.
Description of interventions (Table 1)
The test regimen has a four-drug 2-month intensive
phase followed by a three-drug 2-month continuation
phase. The reference regimen is the standard four-drug
2-month intensive phase with a two-drug 4-monthcontinuation phase. Gatifloxacin is substituted for eth-
ambutol in the intensive phase and is maintained for the
continuation phase. Gatifloxacin is given at a dose of
400 mg per day, irrespective of body weight (1 × 400 mg
once daily). The doses of isoniazid, rifampicin, pyrazina-
mide, and ethambutol follow WHO recommendations,
as indicated in Table 1, and were provided as fixed dose
combination tablets.
All trial drugs were administered orally. The adminis-
tration of both regimens was supervised daily using Dir-
ectly Observed Therapy (DOT). During the intensive
phase, supervision was ensured by either the health cen-
ter staff or a designated representative. During the con-
tinuation phase, treatment was delivered weekly or
biweekly to a supervisor who ensured that daily doses
are taken by the patient.
Clinical and mycobacteriological trial procedures
The timetable of scheduled patient evaluations during
and after the end of treatment is presented in Table 3.
As a result of changes to the prescribing information for
gatifloxacin occurring during the active phase of the
study, the monitoring of blood glucose profiles of
patients recruited into the trial has been intensified and
comprised measurements of blood glucose at screening,
4 h, 7 and 14 days after the first drug intake, and at
months 1, 2, and 3, and end of treatment. Drug safety
has been closely monitored during the course of the
study in compliance with ICH/GCP guidelines.
Trial status
Recruitment for OFLOTUB started on June 2005 and
was concluded on 31 October 2008. A total of 1,836
patients have been recruited into the trial; 316 in Benin,
452 in Guinea, 200 in Kenya, 358 in Senegal, and 510 in
South Africa. In April 2011 all patients completed
24 months of follow-up after the end of treatment.
Results and discussion of methodological issues
Choice of a non-inferiority design
An established highly efficient treatment, that lasts
6 months, exists for pulmonary TB with associated long-
term relapse rates in the region of 5% [10]. Given this, it
is unlikely that a new test regimen will demonstrate su-
periority over the current standard regimen and there-
fore interest lies with showing whether a new regimen is
not inferior to the standard regimen. Shortening treat-
ment duration to less than 6 months is expected to im-
prove adherence to treatment and help with patient
management in overburdened health systems in high TB
prevalence settings. It will also decrease exposure of
patients to toxic drugs. These benefits are considered so es-
sential when developing novel TB regimens that one may
accept some loss of efficacy compared to the standard TB
Table 2 Inclusion and exclusion criteria
Inclusion criteria Patients eligible for inclusion in the trial must fulfil all of the following criteria:
Aged 18 to 65 years (both inclusive) and weighing between 38 and 80 kg
Recently diagnosed, microscopically proven, pulmonary tuberculosis, defined as 2 consecutively
positive sputum smears, of which one must be equal or exceed grade 1
Findings in medical history and physical examination not exceeding grade 2 according to the
Division of Microbiology and Infectious Disease grading system tables (DMID)
Voluntarily signed informed consent to participate in the trial
Females of childbearing potential must have a confirmed negative pregnancy test at the screening
visit and must employ an effective and acceptable method of birth control during the treatment
Laboratory values that do not exceed grade 2 using the Division of Microbiology and Infectious
Disease grading system (DMID) other than for glycaemia, haemoglobin, and potassium levels
Exclusion criteria Patients who meet any of the following criteria are not eligible for the trial:
Patients with a history of TB treatment within the last 3 years
Concomitant infection requiring additional anti-infective treatment (especially antiretroviral medication)
HIV infected patients with WHO stage 3 infection (except those presenting with only
the ‘loss of weight >10% body weight’ criterion) and all patients at WHO stage 4
A history of diabetes mellitus (DM) or non-insulin-dependent diabetes mellitus (NIDDM)
requiring treatment or diet. Additionally patients who have a fasting glucose level less
than 70 mg/dl (3.9 mmol/L) or above 115 mg/dl (6.4 mmol/L) at screening will be excluded
Recreational drug abuse and alcohol abuse that, in the opinion of the investigator,
could prejudice the conduct of the trial in that patient
History of drug hypersensitivity or/and active allergic disease
Impaired renal, hepatic, or gastric function that may, in the opinion of the investigator,
interfere with drug absorption, distribution, metabolism, or elimination
Any other findings in medical history and physical examination exceeding grade 2 in the DMID grading system tables
Patient using the following therapies:
Other antibiotics with known anti-TB activity (that is ofloxacin, moxifloxacin, kanamycin, and so on)
Drugs known to prolong the QT interval (that is antiarrythmics, psychotropics (phenothiazines,
tricyclics, tetracyclics), erythromycin, pentamidine, and halofantrine)
Drugs known to give photosensitivity reactions
Receiving oral corticosteroids for more than 2 weeks immediately prior to inclusion
Use of antacids containing aluminium or magnesium salts or sucralfate
Digoxin
Drugs that are eliminated via tubular secretion (for example, probenecid, cimetidine, ranitidine)
Pregnant or lactating women
Patients with congenital QT interval prolongation defined as> 480 ms
Patients with clinically significant bradycardia defined as <40 bpm
Baseline laboratory values exceeding grade 2 using the Division of Microbiology and Infectious
Disease grading system (DMID) except for haemoglobin and hypokaliaemia for which the limit values are:
Potassium <3.0 mEq/L (>grade 1)
Haemoglobin< 6.5 gm/dl
Separate criteria are required for glycaemia, as listed above
Any other finding considered by the investigator as compromising the participation of the patient in the trial
Any condition rendering the patient unable to understand the nature, scope, and possible
consequences of the trial and to provide consent
Participation in another drug trial within the 3 months before the screening visit
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Table 3 Trial organizational timetable
Screening Treatment Follow-up
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 (G) 18 (T)




Inclusion and exclusion criteria X X
Subject information Informed Consent X
Physical examination X X X X X X X X X X X X X X X X X Xa Xb
Pregnancy test X Xa Xb
HIV test X
Laboratory tests and B/Sc X Xd X X Xf Xa Xb
12-lead ECG X X X Xa Xb
MGIT test X
Sputum smear X X X|e X X X X X X X X X X X X X A Xb
Sputum culture X X X|e X X X X X X X X X X X X Xa Xb
Indirect drug susceptibility testing X X X X X X X X X X X X X X Xa Xb
Chest X-ray X Xa Xb
Randomization X
Adverse events/and events X X X X X X X X X X X X X X X Xa Xb
Concomitant therapy check X X X X X X X X X X X X X X X X Xa Xb
Compliance check X X X X Xb Xb
aOnly for patients randomized in gati arm.
bOnly for patients randomized in control arm.
cLaboratory tests include: full blood count, kalaemia, creatinin, ASAT, ALAT, amylasemia, glycemia (blood glucose is measured twice during the screening).
dBlood glucose levels is measured 4 h after the first dose of medication, and at fasting stage on days 8 and 15, and week 12.
eIf sputum smears are still positive at week 8.
fOnly blood glucose level is measured at week 12.
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The non-inferiority design appears therefore as the best
choice in current development for drug sensitive TB. A
comprehensive discussion on the choice of non-inferiority
design in the TB context is presented elsewhere [11]. All
three current phase III trials in TB drug development inves-
tigating novel chemotherapy combinations, including qui-
nolones, are non-inferiority trials [12-14]. OFLOTUB
is designed to disprove the null hypothesis that the
gatifloxacin-containing drug regimen is clinically inferior by
a given the margin of non-inferiority to the standard treat-
ment, while at the same time decreasing duration of treat-
ment to four months. The alternative hypothesis is that the
gatifloxacin-containing drug regimen is not clinically worse
than (that is non-inferior to) the standard treatment.
Implication of the non-inferiority design on the trial
population to be analyzed
It is widely accepted that in non-inferiority designs there
is no one single least-likely-to-be-biased population ana-
lysis. The intention-to-treat (ITT) approach aims to
minimize differences by including protocol deviations andhence increases the possibility of declaring non-inferiority
between arms. The per-protocol analysis is biased in that
it does not include all randomized patients. In fact, both
population analyses are important and concurring results
are required in order for a non-inferiority trial to be con-
clusive [15].
Complicating matters further, in TB drug trials, a
modified-ITT (MITT) population, a subset of the ITT
population, is analyzed as there is a subset of patients,
identifiable after randomization, who must be excluded
on the basis of their Mycobacterium tuberculosis strain
phenotype. The MITT in OFLOTUB is defined as the
population of patients assigned a randomization number
and dispensed trial medication on at least one occasion
and excluding patients with: (1) confirmed multidrug-
resistant TB on drug sensitivity testing; or (2) rifampicin
resistant, invalid, or contaminated MGIT test results.
The PP population in OFLOTUB is all patients
included in MITT excluding any patient missing more
than two consecutive doses during the intensive phase
or more than six consecutive doses (more than 1 week
of medication) during the continuation phase or taking
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for the test and control regimens, respectively.
Trial measures
Primary efficacy outcome
Over 50 years of TB clinical trials, trial endpoints have
evolved as regimens and diagnosis improved. In 1947, the
endpoints of the BMRC Streptomycin Trial were survival
and clinical/radiological improvement [16]. Nowadays, the
outcomes of interest in assessing the efficacy of new TB
treatments are bacteriological and until recently, TBTable 4 Re-classification decisions concerning the major effic
Situations C
Treatment phase
1 Two cultures + vea at the end of the treatment phase U




3 Death: no information suggesting it was not
related to TB
U
4 Death: documented evidence that it was not
related to TB (for example, car accident)
U
Withdrawals (other than death and before the end of treatment)
5 SAEb for which treatment is stopped U
6 Pregnancy (so treatment is stopped) N
7 Patient withdrawal of consent U
Follow-up phasec
1 Culture -ve + data available for all visits or data
available for last follow-up visit
F
2 Two cultures + ve (at least 1 day apart) during
follow-up and organism id is Mtb
U
3 One culture + ve and organism id is Mtb + second
culture not done or contaminated
U
Death
4 Death and one culture + ve based on most recent
culture result and organism id is Mtb
U
5 Death and culture -ve based on most recent
culture result (or contaminated)
N
o
Withdrawals (other than death):
6 Patient withdrawal of consent and one culture + ve
based on most recent culture result
U
7 Patient withdrawal of consent and culture -ve based




8 Lost during follow-up/moved away from area
and one culture + ve based on most recent culture result
U
9 Lost during follow-up/moved away from area







cDefined among those patients classified as cured at the end of the treatment phasrelapse was the main endpoint of interest. In the initial
version of the OFLOTUB phase III protocol, the primary
endpoint was relapse, defined as two positive cultures in
two sputum collections taken consecutively at least 1 day
apart during the follow-up period, restricted to patients
who had demonstrated cure at the end of treatment
(Table 4). For the purpose of TB treatment trials cure at
the end of treatment is defined as two consecutive cul-
tures negative at the end of treatment which differs from
standard TB control programme definitions of cure.
Lately, the primary outcome was changed to one of theacy outcome
lassification Comments/Date of event
nfavorable Last scheduled day of the treatment
nfavorable Last scheduled day of the treatment
nfavorable Date of death occurrence
nfavorable Date of death occurrence
nfavorable Date when TB treatment stopped
ot assessable Date when TB treatment stopped
nfavorable Date of withdrawal
avorable Date of last culture -ve
nfavorable Date of the first sampling with culture + ve
nfavorable Date of the sampling with the culture + ve
nfavorable Date of the sampling with culture + ve
ot assessable
r Unfavorable
Endpoint committee reviews available data




Favorable till the date of last culture
-ve/Non-assessable the day after the last visit




Favorable till the date of last culture
-veNon-assessable the day after the last visit
e. Cure is defined as two consecutive negative cultures.
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outcome’ endpoint including failure of treatment (either
at 4 or 6 months depending on arm randomized to), re-
currence and other poor outcomes such as loss to follow-
up during the treatment phase, death, and so on. The rea-
son for this was primarily to ensure that all randomized
patients contributed to the analysis of the trial’s primary
endpoint and was following the recommendations made
by the FDA on the submission of a pre-IND file. This has
had an impact in the calculation of the sample size (see
later) but it also forced us to define precise rules for classi-
fication of all patients to ‘favourable’ or ‘unfavourable’ cat-
egories. Table 4 gives a summary of the classification used.
In some situations, the status of the patient would be clas-
sified as not-assessable. An independent endpoints com-
mittee, blinded to the trial arms, will be requested to re-
classify these patients to either category. Table 5 lists all
primary and secondary outcomes. Both of the other
current phase III TB trials also consider a combined out-
come measure, including failure to treatment and relapse,
as their primary outcome of interest [12,13].
Bacteriological diagnosis
False-positive cultures can result from misidentification
of the strain, laboratory cross-contamination, or clerical
error in reporting. Burman et al. found that false-
positive culture results were detected in 13 of 14 DNA
fingerprinting studies that evaluated more than 100
patients, with a median false-positive rate of 3.1% (inter-
quartile range 2.2-10.5%) [17]. In the BMRC trials, half
of the isolated positive cultures (IPC) were seen to be
the results of laboratory cross contamination [18]. The
risk of misclassification is far from negligible and can be
minimized if two positive specimens are available to sup-
port the diagnosis. Therefore, we choose to base the
diagnosis of failure at end of treatment or recurrenceTable 5 Primary and secondary objectives
Efficacy outcomes









Time to a c
Safety outcomes
Primary safety outcome Percentage
Secondary safety outcome The distribufollowing documented cure on two cultures results in-
stead of just one.
Recurrence, relapse, and re-infection
Relapse (reactivation of the original infection) and re-
infection (infection with a new TB strain) are two differ-
ent events leading to the same clinical outcome which
defines, in part, the primary composite outcome of our
trial. An effective regimen should be able to prevent re-
lapse but have no effect on re-infection. In a context of a
significant burden of both TB and HIV, such as in our
site in Durban, the proportion of recurrences due to re-
infection can be high [19,20]. Even if these will be
balanced across arms in a randomized trial, they could
dilute the real regimen effect which is primarily assessed
by relapses. For the same reason ITT analysis might be
biased in non-inferiority trials, considering patients with
re-infection as recurrence might tend to minimize differ-
ences between study arms thereby increasing the possi-
bility of declaring non-inferiority if the percentage of re-
infections is important compared to the percentage of
relapses. This can have a deleterious effect in the context
of the non-inferiority design by forcing non-inferiority.
In order to account for this, we are differentiating re-
lapse from re-infection using a molecular method
(MIRU-VNTR) by comparing baseline and recurrent
strains [21]. However, to allow for direct comparison
with previous trials, recurrence will also be considered
in our analysis.
Duration of the follow-up
We initially took the conservative approach of following
up patients to 24 months after the end of treatment. This
decision has been highly driven by the desire for compar-
ability of our results with the past British Medical Re-
search Council (BMRC) short course chemotherapy trialsof unfavourable outcomes by 24 months following the end of treatment
of unfavourable outcomes by 18 months post randomization
of recurrences by 24 months following the end of treatment. This is
ose individuals who have achieved cure at the end of the treatment
urrence, defined from the date of treatment cure to the date of relapse
of patients with sputum culture conversion at 8 weeks
of patients with sputum smear negativity at 8 weeks
of patients cured by the end of treatment
omposite (unsatisfactory) endpoint of treatment failure or relapse
of adverse events
tion of type and grading of adverse (based on DMID tables)
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first year post treatment and there is an inherent difficulty
in maintaining patients in trials for long durations of
follow-up [23]. Therefore, a shorter follow-up may be suf-
ficient to demonstrate non-inferiority of the test regimen
while simultaneously decreasing the risk of loss of trial
power due to patients lost to follow-up. How long is long
enough? This is a matter of debate. Some propose
6 months after the end of treatment [23]. In the light of
the results of the BMRC trials [22], 1 year of follow-up
seems to capture most of the relapse cases. Therefore, in
addition to the endpoint analysis 24 months after comple-
tion of treatment, we are also assessing our endpoints at
18 months post randomization (that is 12 and 14 months
after completion of the treatment for the control and test
arms, respectively). This will allow for comparison of our
results with those of the other two current phase III trials
where patients are followed up for 18 months after
randomization.Implications of a non-inferiority design on major outcome
measurement
Completeness of outcome data is of critical importance
for non-inferiority trials. This is to ensure non-inferiority
is actually established based on true regimen performance
rather than on missing data, associated loss of power, and
thus decrease the risk of being unable to establish the
given difference in treatments (disprove the null hypoth-
esis). Therefore, in order to minimize the situation of
‘non-assessable’ patients solely due to missing data, we
have incorporated the following measures.
1. Measures to minimize losses during follow-up: we
have introduced a supporter system, usually a member
of the patient’s family, to ensure full adhesion to the trial
procedures by the patient and his/her support network.
All trial sites have experience of observational studies or
trials with long patient follow-up. We have also put into
place a highly active patient tracking system with dedi-
cated field workers who are notified when a patient
misses a visit. We are fortifying this tracking system by
building a further central level of quality control by the
sponsor of the trial. Despite our best efforts we will inev-
itably lose patients, such as those migrating to neighbor-
ing countries in search for work.
2. Measures to minimize unavailability of bacterio-
logical results for each patient at each visit. During the
treatment phase two sputum samples were collected per
patient and per visit at regular time points and cultured.
Similarly, during the follow up phase, two sputum sam-
ples were collected per patient at regular time points
and cultured (Table 3). Additional sputum samples are
collected in cases of suspected relapse when the patient
either presents with clinical symptoms of TB or has apositive sputum smear. This should minimize the risk of
unavailable culture results.Open-label design
The trial is open-label (non-blinded) with respect to clinic
staff reviewing patients at scheduled and unscheduled vis-
its and the patients themselves. Laboratory technicians are
blinded to the treatment regimen the patient is receiving.
Double-blinding is favored in many trial situations; however
it was felt that, with this trial design of a treatment shorten-
ing regimen, a non-blinded design was preferable. A
patient’s knowledge that they are receiving a 4-month regi-
men may result in better adherence which arguably may
not occur in a blinded design. This, to our view, is one of
the most important aspect to capture when assessing a
treatment shortening regimen. Nevertheless, one disadvan-
tage of this design is that clinic staff are not blinded to
treatment arm and may make different clinical decisions in
caring for patients depending on the regimen a patient is
receiving. For example, clinic staff may more readily retreat
a patient, following the end of treatment if they were receiv-
ing the 4-month regimen which would penalize the test
regimen arm. In light of this, our endpoints are based on
mycobacteriological results (smear or culture). When
mycobacteriological evidence is missing, endpoint classifi-
cation has been defined and is discussed previously.Sample size determination (initial and revised
calculations)
All sample size calculations were based on a power of
80% and a one-sided significance level of 2.5%. The ini-
tial sample size assumptions, presented in Table 6, were
based on the outcome of relapses by 24 months follow-
ing the end of treatment. Due to the revision of the pri-
mary outcome, following discussions with regulatory
authorities, the sample size calculation also had to be
revised. Revised assumptions had to take into consider-
ation the composite ‘unfavourable’ outcome of treatment
failure, recurrence or other ‘unfavourable’ scenarios, as
listed in Table 4 by 24 months following the end of
treatment. We used summarized internal blinded trial
data from the interim analysis performed in May 2008 at
the request of the DMC, to inform revised sample size
assumptions (Table 6). We estimated the proportion
with the revised unfavorable outcome by 24 months to
be 20%. To account for the revised endpoint, margin of
non-inferiority (delta) was increased to 6% (from 3%). Fi-
nally, losses to follow up (LTFU) were decreased to 15%
(from 25%) since, patients who have died or been lost
during treatment, and would have been considered
LTFU for the original calculation, are considered as un-
favorable for the revised outcome. Under revised
assumptions we estimate 697 patients per arm (1,394
Table 6 Original and revised sample size substantiation
Original calculation Revised calculation
Outcome Relapses at 24 months
after end of treatment
‘Unfavourable’ events at 24
months after end of treatment (MITTa)
‘Unfavourable’ events 24
months after end of treatment (PPb)
Events in control arm (%) 5% 20% 14%
1-sided significance level 2.5% 2.5% 2.5%
Power 80% 80% 80%
Non-inferiority margin δ 3% 6% 6%
Patients overall (n) 1,656 1,394 1,050
Adjustment for LTFUc 20% 15%d 27%d
Patients after adjustment for LTFU (n)d 2,070 1,640 1,438
aModified intent to treat.
bPer protocol.
cLost to follow-up.
dIn the revised sample size calculation, patients LTFU are re-classified as unfavorable or non-assessable. Therefore LTFU for the revised calculation refers to the
adjustment made on the percentage of patients non-assessable.
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the MITT analysis requires 1,640 patients overall.
However, since the per-protocol (PP) population ana-
lysis in non-inferiority studies is equally important to
the MITT, we need to ensure sample size gives adequate
power for the PP analysis as well. Deaths, losses, and
withdrawals due to serious adverse events during treat-
ment (estimated 6%) will most probably not satisfy the
PP adherence criteria, as well as genuine non-adherers
(estimated 6%) not included in the above categories.
Based on these estimates, drawn from patient manage-
ment logs, a further 12% of patients satisfying the MITT
will be excluded from the PP analysis (Table 6). Further-
more, we estimate the proportion of patients with un-
favorable outcome will be reduced to approximately 14%
since deaths, losses, and withdrawals during treatment
(unfavorable outcomes) are most probably excluded
from this population analysis. For a power of 80% and
delta of 6% we would require a total of 1,050 (525 per
arm). Adjusting for 27% (15%+ 12%) of patients
excluded the PP requires 1,438 patients.
The total 1,836 patients recruited give OFLOTUB
enough power for both the MITT and PP analyses. An
independent review by a statistician to confirm the revi-
sion of sample size was undertaken and the DMC was
kept informed throughout the process.
Conclusion
We have presented in this manuscript key questions we
were required to answer while designing OFLOTUB,
and our reasoning for the decisions we made. There is
no single answer for any of these design questions in the
context of phase III TB drug trials and this is demon-
strated by current consultations within regulatory agen-
cies. When shortening TB treatment, we are advocating
for a non-inferiority, non-blinded design, with a com-
posite unfavorable endpoint assessed 12 months posttreatment completion, and added trial procedures specif-
ically aiming to: (1) minimize endpoint unavailability;
and (2) distinguish between relapse and re-infection.
With our paper we are adding to the sparse published
literature on the design of pivotal TB drug trials and
hope to inform decision making for such future trials.
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